ÂÜÀòÂÒÂ×

Oliver Zill is an accomplished computational biologist with extensive experience in the life sciences sector. Currently serving as Vice President of Computational Biology at ImmuneBridge since February 2024, Zill is also the Founder and Principal at init.bio, focusing on enhancing drug and diagnostic development through scientific strategy and operations. Previous roles include Senior Scientist and Group Leader at Genentech, where Zill led initiatives on individualized neoantigen vaccines and TCR T-cell therapies, as well as Bioinformatics Scientist at Guardant Health, spearheading clinical utility studies on circulating tumor DNA. Zill's academic foundation includes a Ph.D. in Molecular Biology from the University of California, Berkeley, and a Bachelor of Arts in Biology from Columbia University.